Supplementary Table S1 from METTL1-Mediated M7g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433516

2023-01-01

Abstract:This file shows the antibodies used in the study.

What problem does this paper attempt to address?

Supplementary Table S2 from METTL1-Mediated M7g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433513.v1

2023-01-01

Abstract:This table shows a list of primer and probe sequence used in our study.
Supplementary Materials from METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433519.v1

2023-01-01

Abstract:This file describes supplementary methods and materials.
Supplementary Figures from METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433522

2023-01-01

Abstract:This file describes supplementary figures.
METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.CAN-22-0963

2023-01-04

Abstract:The tyrosine kinase inhibitor lenvatinib is a first-line drug for treating patients with advanced hepatocellular carcinoma (HCC). However, its efficacy is severely hampered by drug resistance. Insights into the molecular mechanisms underlying lenvatinib resistance could provide new strategies to improve and prolong responses. Here, we performed unbiased proteomic screening of parental and lenvatinib-resistant HCC cells and discovered that methyltransferase-like protein-1 (METTL1) and WD repeat domain 4 protein (WDR4), the two key components of the tRNA N7-methylguanosine (m7G) methyltransferase complex, were dramatically upregulated in lenvatinib-resistant cells. METTL1 knockdown overrode resistance by impairing the proliferation capacity of HCC cells and promoting apoptosis under lenvatinib treatment. In addition, overexpression of wild-type METTL1 but not its catalytic dead mutant induced lenvatinib resistance. Animal experiments including hydrodynamic injection, subcutaneous implantation, and orthotopic xenograft mouse models further demonstrated the critical function of METTL1/WDR4-mediated m7G tRNA modification in promoting lenvatinib resistance in vivo. Mechanistically, METTL1 promoted translation of EGFR pathway genes to trigger drug resistance. This work reveals the important role of METTL1-mediated m7G tRNA modification in promoting lenvatinib resistance and provides a promising prediction marker and intervention target for resistance. Significance: Upregulation of tRNA m7G methyltransferase complex components METTL1 and WDR4 promotes lenvatinib resistance in HCC and confers a sensitivity to METTL1 targeting, providing a promising strategy to override resistance.
Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505085

2023-01-01

Abstract:Figure S4 shows the long-term role of anti-MET VHH pool in treating mice.
Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505076

2023-01-01

Abstract:Figure S7 shows the model of anti-MET VHH pool overcoming MET-targeted cancer therapeutic resistance.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
METTL3-m6A-EGFR-axis Drives Lenvatinib Resistance in Hepatocellular Carcinoma.

Lina Wang,Qingxia Yang,Qianying Zhou,Fei Fang,Kai Lei,Ziqin Liu,Gaomin Zheng,Lefan Zhu,Jihui Huo,Xiaoxing Li,Sui Peng,Ming Kuang,Shuibin Lin,Manling Huang,Lixia Xu

DOI: https://doi.org/10.1016/j.canlet.2023.216122

IF: 9.756

2023-01-01

Cancer Letters

Abstract:Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy efficiency in clinic. N6-methyladenosine (m6A) is the most abundant mRNA modification. Here, we aimed to investigate the modulatory effects and underlying mechanisms of m6A in lenvatinib resistance in HCC. Our data revealed that m6A mRNA modification was significantly upregulated in the HCC lenvatinib resistance (HCC-LR) cells compared to parental cells. Methyltransferase-like 3 (METTL3) was the most significantly upregulated protein among the m6A regulators. Either genetic or pharmacological inhibition of m6A methylation through METTL3 deactivation in primary resistant cell line MHCC97H and acquired resistant Huh7-LR cells decreased cell proliferation and increased cell apoptosis upon lenvatinib treatment in vitro and in vivo. In addition, the specific METTL3 inhibitor STM2457 improved tumor response to lenvatinib in multiple mouse HCC models, including subcutaneous, orthotopic and hydrodynamic models. The MeRIP-seq results showed that epidermal growth factor receptor (EGFR) was a downstream target of METTL3. EGFR overexpression abrogated the METTL3 knocked down-induced cell growth arrest upon lenvatinib treatment in HCC-LR cells. Thus, we concluded that targeting METTL3 using specific inhibitor STM2457 improved the sensitivity to lenvatinib in vitro and in vivo, indicating that METTL3 may be a potential therapeutic target to overcome lenvatinib resistance in HCC.
Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Ping Lu,Chao Ge,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395144.v1

2023-01-01

Abstract:PDF file - 82K, Antibodies used in this study
Table S1 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,YaoJun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826111.v1

2023-01-01

Abstract:Representativeness of Study Participants
Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418429.v1

2023-01-01

Abstract:Several tables contain the nucleotide sequences, antibodies information, LncRNA expression profiles, LncRNA screening, the correlation between MetaLnc9 and clinicopathological features, the mass spectrometric analysis results, RNA-seq analysis, KEGG and GSEA analysis.
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Table 6 from linc00869 Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

Xiaowen Shao,Yamei Dang,Tingting Zhang,Nan Bai,Jianing Huang,Mengya Guo,Li Sun,Minghe Li,Xiao Sun,Xinran Zhang,Feng Han,Ning Zhang,Hao Zhuang,Yongmei Li

DOI: https://doi.org/10.1158/1541-7786.25325105

2024-01-01

Abstract:Table of key reagents and resources.
<scp>METTL1</scp> is required for non‐homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy

Junbin Liao,Yang Yi,Xin Yue,Xiaoxue Wu,Meiyan Zhu,Yong Chen,Sui Peng,Ming Kuang,Shuibin Lin,Zhenwei Peng

DOI: https://doi.org/10.1002/hep.32615

IF: 17.298

2022-01-01

Hepatology

Abstract:Radiotherapy is an increasingly essential therapeutic strategy in the management of hepatocellular carcinoma (HCC). Nevertheless, resistance to radiotherapy is one of the primary obstacles to successful treatment outcomes. Hence, we aim to elucidate the mechanisms underlying radioresistance and identify reliable biotargets that would be inhibited to enhance the efficacy of radiotherapy in HCC.From a label-free quantitative proteome screening, we identified transfer RNA (tRNA; guanine-N [7]-) methyltransferase 1 (METTL1), a key enzyme for N7-methylguanosine (m7 G) tRNA modification, as an essential driver for HCC cells radioresistance. We reveal that METTL1 promotes DNA double-strand break (DSB) repair and renders HCC cells resistant to ionizing radiation (IR) using loss-of-function and gain-of-function assays in vitro and in vivo. Mechanistically, METTL1-mediated m7 G tRNA modification selectively regulates the translation of DNA-dependent protein kinase catalytic subunit or DNA ligase IV with higher frequencies of m7 G-related codons after IR treatment, thereby resulting in the enhancement of nonhomologous end-joining (NHEJ)-mediated DNA DSB repair efficiency. Clinically, high METTL1 expression in tumor tissue is significantly correlated with poor prognosis in radiotherapy-treated patients with HCC.Our findings show that METTL1 is a critical enhancer for HCC cell NHEJ-based DNA repair following IR therapy. These findings give insight into the role of tRNA modification in messenger RNA translation control in HCC radioresistance.
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Supplementary Table S2 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515862

2024-01-01

Abstract:Table S2. Primers used in this study.
Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Mingxiang Ye,Yong Zhang,Xinxin Zhang,Jianbin Zhang,Pengyu Jing,Liang Cao,Nan Li,Xia Li,Libo Yao,Jian Zhang

DOI: https://doi.org/10.1158/0008-5472.22413117

2023-01-01

Abstract:This supplementary tables contain shRNAs, siRNAs, primers sequences and antibody resources.
Supplementary Table 1 from pik3ca Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Jian‐Xin Xu,Yan Wang,Youliang Wang,Tao Liu,Nai‐Ben Ming,Man-Sheng Li,Lin Li,Fei‐Jiao Ge,Chun Gong,Jun-Yan Gu,Ru Jia,He-Fei Wang,Yuling Chen,Rongrui Liu,Chuanhua Zhao,Zhao-Li Tan,Jian Yang,Zhu Yu,Shuji Ogino,Zhenyun Qian

DOI: https://doi.org/10.1158/1078-0432.22463441.v1

2023-01-01

Abstract:Clinical information of validation cohort
Figure S11 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,YaoJun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826168.v1

2023-01-01

Abstract:Integration analysis of malignant hepatocytes.
Supplementary Table S8 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515844.v1

2024-01-01

Abstract:Table S8. The potential functional role of rs3744797 by VannoPortal database.

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Table S2 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Materials from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

METTL3-m6A-EGFR-axis Drives Lenvatinib Resistance in Hepatocellular Carcinoma.

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Table S1 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 6 from <i>linc00869</i> Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

<scp>METTL1</scp> is required for non‐homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Table S2 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Supplementary Table 1 from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Figure S11 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Supplementary Table S8 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S1 from METTL1-Mediated M&lt;sup&gt;7&lt;/sup&gt;g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Table S2 from METTL1-Mediated M&lt;sup&gt;7&lt;/sup&gt;g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma